SUNNYVALE, Calif. , June 6, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Sandeep Chalke , the company's new senior vice president, chief commercial officer. As a material inducement to Mr.
SUNNYVALE, Calif. , June 15, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Franco N. Palomba has joined the company as vice president, chief accounting officer & controller. Mr. Palomba will be responsible for the controllership function, including the global
SUNNYVALE, Calif. , July 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new clinical studies presented at the 15 th Congress of the International Stereotactic Radiosurgery Society (ISRS) in Milan, Italy reinforce the value of the company's CyberKnife® platform
SUNNYVALE, Calif. , July 27, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and fiscal year 2022, ended June 30, 2022 , after the market close on August 10, 2022 . Management will host a conference call to review the results at 1:30
Accuray Will Anchor Hub That Will Unite Companies From the MedTech , Pharma and Biosciences Sectors, Physicians and Scientists SUNNYVALE, Calif. , Sept. 7, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is joining forces with Genolier Innovation Hub , a
SUNNYVALE, Calif. , Sept. 14, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Seth Blacksburg, M.D., MBA has joined the company as vice president, chief medical officer for the Americas ( North and South America ) region. Dr.
World's Only Robotic Radiation Therapy Device Delivers Extremely Precise Treatments in Just 1 to 5 Out- Patient Sessions SUNNYVALE, Calif. , Sept. 30, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is expanding its global footprint with the introduction of its
SUNNYVALE, Calif. , Oct. 6, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a key opinion leader (KOL) discussion with analysts and investors on Monday, October 24, 2022 , in conjunction with the American Society of Radiation Oncology (ASTRO)
Latest research published in The Lancet Oncology : suggests bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment Almost 20 years of global clinical data: shows the non-surgical CyberKnife platform
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
